Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Lunac Therapeutics, a UK-based anticoagulant drug discovery spinout of University of Leeds, formally launched yesterday having raised £2.7m ($3.5m) co-led by the university and Epidarex Capital for the first close of its series A round. Lunac’s anticoagulants will target a blood-clotting protein called Factor XII to address the risk of bleeding prevalent with existing drugs. The spinout advances research by Helen Philippou, professor at University of Leeds’s School of Medicine, and Richard Foster, an associate professor at the institution’s School…
